HomeCompareATHA vs SBUX

ATHA vs SBUX: Dividend Comparison 2026

ATHA yields 29.63% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $37.4K in total portfolio value· pulled ahead in Year 10
10 years
ATHA
ATHA
● Live price
29.63%
Share price
$6.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$129.6K
Annual income
$16,960.56
Full ATHA calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — ATHA vs SBUX

📍 SBUX pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATHASBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATHA + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATHA pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHA
Annual income on $10K today (after 15% tax)
$2,518.52/yr
After 10yr DRIP, annual income (after tax)
$14,416.48/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $46,049.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHA + SBUX for your $10,000?

ATHA: 50%SBUX: 50%
100% SBUX50/50100% ATHA
Portfolio after 10yr
$148.3K
Annual income
$44,048.51/yr
Blended yield
29.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

ATHA
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$13.33
+97.5% upside vs current
Range: $3.00 — $33.00
Altman Z
-18.3
Piotroski
1/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHA buys
0
SBUX buys
0
No recent congressional trades found for ATHA or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATHASBUX
Forward yield29.63%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$129.6K$167.0K
Annual income after 10y$16,960.56$71,136.45
Total dividends collected$88.0K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$13.33$104.00

Year-by-year: ATHA vs SBUX ($10,000, DRIP)

YearATHA PortfolioATHA Income/yrSBUX PortfolioSBUX Income/yrGap
1$13,663$2,962.96$11,121$420.68+$2.5KATHA
2$18,403$3,783.44$12,548$648.40+$5.9KATHA
3$24,454$4,762.59$14,440$1,013.98+$10.0KATHA
4$32,080$5,914.49$17,068$1,617.30+$15.0KATHA
5$41,577$7,251.43$20,912$2,649.52+$20.7KATHA
6$53,271$8,783.33$26,875$4,499.29+$26.4KATHA
7$67,517$10,517.46$36,771$8,014.12+$30.7KATHA
8$84,701$12,458.13$54,542$15,197.11+$30.2KATHA
9$105,237$14,606.49$89,602$31,242.49+$15.6KATHA
10← crossover$129,564$16,960.56$167,011$71,136.45$37.4KSBUX

ATHA vs SBUX: Complete Analysis 2026

ATHAStock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Full ATHA Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this ATHA vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHA vs SCHDATHA vs JEPIATHA vs OATHA vs KOATHA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.